| |
Ethanol and acetaldehyde levels in blood and urine have been
evaluated in 9 volunteers following administration of Liv.52 and
placebo on the evening of the study and on the following morning.
On the following morning the volunteers scored their symptoms and
completed visual analogue scales. Single dose and multiple dose
studies were done.
Liv.52 produced a considerable reduction in blood
and urine levels of ethanol and acetaldehyde after 12 hours. It
is possible that Liv.52 prevents the binding of acetaldehyde, bringing
about higher initial blood levels followed by rapid elimination.
It reduced the hangover symptoms.
Many epidemiological
studies have established a relationship between excessive alcohol
intake and liver disease1, although there seems to be
a weak relationship between the extent and duration of alcohol intake
and severity of liver injury2. Acetaldehyde has long
been suspected to be the causative agent of alcoholic liver disease3.
For the same ethanol intake, chronic alcoholic users have been shown
to have lower blood ethanol and higher blood acetaldehyde levels
compared to non-alcohol users4. A similar change in alcohol
metabolism has recently been described in moderate social drinkers5.
In the same study, Liv.52 (The Himalaya Drug Co.), a herbal formulation
of several plant principles prepared according to Ayurvedic concepts,
was shown to raise the blood ethanol level and to cause rapid elimination
of acetaldehyde. It was also shown to enhance the rate of absorption
of ethanol.
Acetaldehyde has unpleasant
effects on the central nervous system and its persistence may be
responsible for hangover symptoms in moderate social drinkers6.
The present study was designed to check the effect of Liv.52 on
ethanol and acetaldehyde levels in blood and urine, and on hangover
symptoms.
Nine healthy male subjects,
mean age of 39.6 years (range 31 – 57 years), and mean weight 64.4
kg (range 54 - 76 kg), volunteered for the study. All the subjects
consumed moderate alcohol (40 - 100 g per week) socially and had
occasionally experienced hangover effects. Chronic alcoholics and
those who did not drink socially were excluded. The complete protocol
of the study was discussed and written consent was obtained from
each volunteer before entering the study.
One batch of a particular
brand of Indian whisky was used throughout the study. The ethanol
content determined by gas chromatography was 37.5 g/100ml. On each
study evening, the volunteers consumed four portions of whisky,
each of 60ml. Each portion was mixed with an equal volume of soda
and ice and was consumed within 30 min. The first two portions were
consumed on an empty stomach. Measured snacks were permitted with
the last two portions to avoid severe gastric symptoms.
Liv.52 is an Ayurvedic
formulation containing active principles of the following herbs:
Capparis spinosa, Cichorium intybus, Solanum nigrum, Cassia occidentalis,
Terminalia arjuna, Achillea millefolium, Tamarix gallica and
Phyllanthus amarus (formerly wrongly identified as Phyllanthus
niruri). These ingredients are known to exert a hepatoprotective
action (Subbarao, V.V. 1975, unpublished data).
|
Table 1: Mean blood
concentrations and total urinary excretion of ethanol and
acetaldehyde
|
| |
Ethanol
|
Acetaldehyde
|
|
Placebo
|
Liv.52
single dose
|
Liv.52
multiple dose
|
Placebo
|
Liv.52
single dose
|
Liv.52
multiple dose
|
|
Blood (mg/100
ml)
|
| 1 hour |
75.00
± 5.25
|
86.2
± 4.03
|
95.3
± 3.99
|
5.14
± 0.38
|
5.29
± 0.38
|
5.96
± 0.66
|
| 12 hours |
30.7
± 7.7
|
5.39
± 1.52
|
4.82
± 2.70
|
2.68
± 0.38
|
1.59
± 0.22
|
0.78
± 0.23
|
| Urine
(mg)
4-12 hours
|
110
± 20.2
|
69.9
± 21.0
|
24.8
± 7.38
|
383
± 74.6
|
285
± 61.1
|
142
± 24.6
|
|
Table 2: Showing the mean distance from the
hangover point on the visual analogue score and mean symptom
score
|
| |
Placebo
|
Liv.52 - multiple dose
|
| Mean distance (mm) |
236 (± 32.7)
|
288 (± 29.8)
|
| Mean score |
3.81 (± 0.81)
|
2.44 (± 0.65)
|
The dose of Liv.52 was
6 tablets taken 2 hour prior to consumption of alcohol in the single
dose study and 3 tablets for 14 days for the multiple dose study.
Six tablets of an identical appearing placebo were given 2 hour
prior to commencing the drinks on a placebo day.
The study was performed
on 3 occasions: Day 1 following a single dose of placebo, Day 2
after a single dose of Liv.52 tablets and Day 3 after 15 days of
Liv.52 treatment. No alcohol was permitted 24 hour before each trial
day.
On each trial day, 3
volunteers reported to the Clinical Pharmacology facility (two air-conditioned
bedrooms, lounge, recreation facility and pharmacodynamic test laboratory)
at 17.00 hour after eating their usual lunch at 13.00 hour. The
drug was administered (placebo or Liv.52) at 17.30 hour. At 20.30
hour after drinking two portions of whisky, venous blood was collected
for ethanol and acetaldehyde estimation. A standard dinner was served
at 22.00 hour after drinking the 4 portions of whisky (total ethanol
90 g). The volunteers retired at 23.00 hour. Blood was collected
1 hour after drinking the whisky. At 7.00 hour the next morning
they were woken up and venous blood was again collected for estimation
of ethanol and acetaldehyde. Urine was collected from 23.00 to 7.00
hour. They were estimated immediately after collection by head space
Gas Chromatography8. Thereafter, the volunteers filled
up the symptom scores and marked visual analogue scales.
Tests for hangover
1. A pair of words designating
opposite feelings was selected and written at the two ends of a
100 mm line. The end of the line associated with the word designating
hangover was called the 'hangover point'. Four such pairs of words
were used. To overcome the right-hand effect, two hangover points
were on the left and two hangover points on the right. The distance
of the mark made by each subject from the hangover point was taken
as the parameter.
2. A list of 10 symptoms
commonly associated with hangover was given to the volunteers to
score from '0' (zero) indicating absent, to '3' indicating severe.
Unpleasant feelings in
the morning following excessive alcohol consumption are commonly
referred to as the hangover effect. In gross form it is estimated
to occur in approximately 50% of cases6,9, but the use
of sensitive tests may detect it in the majority of persons after
consumption of about 1.5 g/kg of ethanol8,10. In the
present study approximately 1.5 g/kg ethanol was consumed. Four
visual analogue scales and scores of ten common symptoms were recorded
to compare the hangover effect.
As expected, Liv.52 administration
caused higher ethanol levels in the blood at 1 hour, especially
after multiple doses, possibly by inhibiting the presystemic metabolism
of ethanol5. Acetaldehyde levels were also higher (non-significant).
At 12 hour, Liv.52 treatment caused a significantly reduced level
of ethanol and acetaldehyde in the blood and in the 4-12 hours urine
specimens. The single dose treatment had a similar but less pronounced
effect.
Acetaldehyde is known
to form adducts with cell proteins9,11, which may lead
to cellular damage. The results suggest that Liv.52 prevent the
binding of acetaldehyde, causing a higher initial blood level and
rapid elimination subsequently.
Lower levels of ethanol
and acetaldehyde in the blood at 12 hours are reflected in the decreased
symptom scores and the change in the visual analogue score. The
last two observations are indicative of a reduced hangover after
Liv.52 treatment. The differences did not reach statistical significance
due to the small number of subjects, low level of the hangover effect
and variability between volunteers.
Although a crude formulation
has been used, the results are significant and interesting. Further
work on ethanol and acetaldehyde binding and clearance, and the
effects of Liv.52 on them is warranted.
- Charles, S. and Lieber, M.D., Biochemical and molecular basis
of alcohol-induced injury to liver and other tissues. N. Engl.
J. Med. (1988): 25, 1639-1650.
- Lelbach, W.K., Cirrhosis in the alcoholic and its relation to
the volume of alcohol abuse. Ann. N.Y. Acad. Sci. (1975):
285, 85-105.
- Diluzio, N.B. and Hartman, A.D., Role of lipid peroxidation
in the pathogenesis of ethanol-induced fatty liver. Fed. Proc.
(1967): 26, 1436-1438.
- William, J. (1984): Liver disorders in alcoholism. In: Rosalki
S.B. (ed.), Clinical chemistry of alcoholism. Churchill Livingstone,
New York., p. 258-270.
- Chauhan, B.L. and Kulkarni, R.D., Effect of Liv.52, a herbal
preparation, on absorption and metabolism of ethanol in humans.
Eur. J. Clin. Pharmacol. (1991): 40, 189.
- Li, T.K. (1977): Enzymology of human alcohol metabolism: In:
Meister A. (ed.), Alcoholism. Churchill Livingstone, New York.,
p. 19-56.
- Mendenhall, C.L., Macgee, J. and Green, E.S., Simple, rapid
and sensitive method for the simultaneous quantitation of ethanol
and acetaldehyde in biological materials using Head Space Gas
Chromatography. J. Chromatogr. (1980): 190, 197-200.
- Smith, S.C. and Barnes, G.M., Signs and symptoms of hangover:
prevalence and relation to alcohol use in general population.
Drug Alc. Depend. (1983): 11, 249-269.
- Ylikahri, R.H., Huttumen, M.D., Erikson C.J.P. and Nikkila,
E.A., Metabolic studies on pathogenesis of hangover. Eur. J.
Clin. Invest. (1974): 4, 93-100.
- Sorrell, M.F. and Tuma, D.J. (1987): The functional implication
of acetaldehyde binding to all constituents. In: Rubin, E. (ed.),
Alcohol and cells, N.Y. academy of Science, p. 50-62.
|
Liv.52 |